Document:

EX-10.11

 Exhibit 10.11 

EMPLOYMENT AGREEMENT 

This EMPLOYMENT AGREEMENT (the “Agreement”), made as of August 27, 2019, is entered into between TDTx, Inc., a Delaware
corporation (the “Company”), and Raken B. Modi (AKA Rick Modi) (the “Executive”). 
 In consideration of
the mutual covenants and promises contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties to this Agreement, the parties agree as follows: 

1. Employment/Duties. During the Employment Period (as defined below), the Executive shall serve as Chief Executive Officer of the
Company and shall have all the duties, responsibilities and authority commensurate with such position and such additional duties as may be determined by the Company’s Board of Directors (“Board of Directors”). The Executive
shall be based at the Company’s principal place of business in the greater Boston, Massachusetts metropolitan area, or such place as the Executive and the Company’s Board of Directors shall determine. The Executive shall report to, and be
subject to the general supervision of, the Company’s Board of Directors. 
 The Executive agrees to devote substantially all of his
business time, attention and energies to the business and interests of the Company during the Employment Period; provided, however, that the Executive may be permitted to engage in other activities, including membership on boards of
directors of other businesses or non-for-profit organizations, so long as such activities (i) do not materially interfere with the performance of the
Executive’s duties under this Agreement, (ii) do not create a conflict of interest with the Company and (iii) have been disclosed to and approved in advance by the Board of Directors. The Executive agrees to abide by the rules,
regulations, personnel practices and policies of the Company, as adopted and amended from time to time by the Company, provided, that such rules, regulations, practices and policies have been disclosed to the Executive. 

2. Effective Date/Period of Employment. This Agreement will become effective as of August 27, 2019 (the “Effective
Date”), and shall continue until the one (1) year anniversary of the Effective Date (“Initial Term”). After the Initial Term, the term (“Term”) of this Agreement will be renewed annually until
terminated in accordance with the provisions of Section 4 (the “Employment Period”), subject to Section 5. As a condition of employment with the Company, the Executive will be required (a) to sign the Company’s
Invention Assignment, Non-Disclosure, and Business Protection Agreement attached hereto as Exhibit A (the “Business Protection Agreement”), which among other things, prohibits
unauthorized use or disclosure of Company proprietary information; (b) to sign and return a satisfactory USCIS Form I-9 attached hereto as Exhibit B and provide sufficient documentation when you
report to work establishing your employment eligibility in the United States of America as required by law (enclosed is a list of acceptable Form I-9 documentation); and (c) to provide satisfactory proof
of the Executive’s identity as equired by law. 

 Compensation and Benefits. 

3.1 Base Salary. The Company will pay the Executive a salary at the weekly rate of $455.00 until the date on which the Company
consummates a Minimum Financing (as defined below). A “Minimum Financing” means the issuance of equity interests (or debt securities convertible into equity interests) in one or a series of related transactions, the principal
purpose of which is to raise capital, which transaction or series of related transactions result in the Company receiving gross proceeds of not less than $3,000,000 (inclusive of the principal amount of the notes that will convert into equity
in connection with the consummation of the Minimum Financing). Upon a Minimum Financing, the Executive’s salary will be adjusted to the corresponding rate set forth on Schedule 1 (as adjusted, the “Base Salary”). In the event
that a Minimum Financing has not been consummated by December 31, 2019, your salary will be at such rate as is mutually agreed by you and the Company (but not less that the weekly rate set forth above, or the rate set forth in Schedule 1,
whichever is applicable), payable in accordance with the Company’s standard payroll schedule and subject to required tax withholding and other authorized deductions. 

3.2 Annual Bonus Opportunity. During the Employment Period, provided that the Company has closed a Minimum Financing, in addition to the
Executive’s Base Salary, the Executive will be eligible to be considered for an annual (fiscal year) incentive cash bonus with a target of 50% of his annual salary. The bonus (if any) will be awarded based on objective and/or subjective
criteria established by the Company’s Board of Directors. Any bonus for the fiscal year in which the Executive’s employment begins or terminates will be prorated, based on the number of days the Executive is employed by the Company during
that fiscal year. Any bonus for a fiscal year will be paid within 21⁄2 months after the close of that fiscal year. The Executive hereby acknowledge and agrees that
nothing contained herein confers upon the Executive any right to an annual bonus in any year, and that whether the Company pays the Executive an annual bonus and the amount of any such annual bonus will be determined by the Company’s Board of
Directors in its sole discretion. 
 3.3 Equity Compensation. In connection with entering into this agreement and as mutually agreed
upon consideration for your undertaking the obligations set forth in Sections 4.2 and 4.3 of the Business Protection Agreement, the Company will recommend to the Board of Directors or Compensation Committee that it issue the Executive 117,500 shares
of the Company’s common stock (the “Restricted Shares”), at a per-share purchase price equal to the fair market value of a share of the Company’s common stock on the date of issuance
(as determined by the Board of Directors or Compensation Committee in its sole discretion and which is currently expected to be approximately $0.001 per share), provided that the Executive is providing services to the Company on the date of grant.
Subject to the Executive’s commencement and continued employment with the Company through the applicable vesting dates; the Restricted Shares will vest (e.g., the Restricted Shares will no longer be subject to the Company’s purchase right
at the original cost of the Restricted Shares) as follows: 
 5% of the Restricted Shares will vest as of the commencement of the Executive’s
employment with the Company; 

  
 Page 2 

 10% of the Restricted Shares will vest upon the consummation by the Company of a Minimum Financing that
results in the Company receiving gross proceeds of not less than $5,000,000, and the remaining 85% of the Restricted Shares will vest in equal monthly installments over the 36 months commencing on the date of execution of that certain
Exclusive License Agreement by and between the Company, Lonza Houston, Inc., Massachusetts Eye and Ear Infirmary, Inc. and The Schepens Eye Research Institute, Inc. (the “License Agreement”). For clarity, the 2.36111% of the
Restricted Shares will vest on each monthly anniversary of the License Agreement. 
 The Restricted Shares will otherwise be subject to the terms and
conditions of a restricted stock purchase agreement to be entered into between Executive and the Company. 
 Further, the Executive may be eligible to
receive additional equity grants in the form of options or capital stock from time to time as shall be determined by the Company’s Board of Directors based on the Company’s annual performance, and subject to such vesting, exercisability,
and other provisions as the Board of Directors may determine. In addition to the foregoing and subject to the Executive’s continued service to the Company, the Board of Directors will review the Executive’s total equity stake on a periodic
basis to determine whether the Executive’s aggregate ownership interest is competitive with that of other similarly situated Chief Executive Officers. 

3.3 Benefits. During the Employment Period, the Executive shall be entitled to participate in all benefit programs that the Company
makes available to its employees, if any, to the extent that Executive’s position, tenure, health and other qualifications make the Executive eligible to participate, and the Company agrees to obtain D&O insurance as soon as the Board of
Directors determines it is financially feasible. The Executive shall be entitled to take paid vacation of 15 days and consistent with the Company’s employee benefits policy in addition to customary business holidays approved by the Board of
Directors for the Company’s employees generally. The Executive shall notify the Board of Directors when the Executive intends to take vacation. 

3.4 Reimbursement of Expenses. The Company shall reimburse the Executive for all reasonable travel, entertainment and other expenses
incurred or paid by the Executive in connection with, or related to, the performance of the Executive’s duties, responsibilities or services on behalf of the Company under this Agreement, in accordance with policies and procedures, and subject
to reasonable limitations, adopted by the Company from time to time. Additionally, you will be reimbursed for all reasonable and necessary out-of-pocket expenses
incurred by you in the performance of your obligations under this letter agreement. In the event that the Company’s headquarters is located at a distance more than 50 miles from Boston, MA, you will be reimbursed for all reasonable and
necessary out-of-pocket expenses incurred by you to commute or relocate to a location near the Company’s headquarters. 

3.5 Withholding. All salary, bonus and other compensation payable to the Executive during the Employment Period shall be subject to
applicable required deductions for state and federal withholding tax, social security and all other employment taxes and payroll deductions. 

4. Termination of Employment Period. The employment of the Executive by the Conpany pursuant to this Agreement shall terminate upon the
occurrence of any of the following: 

  
 Page 3 

 4.1 By the Company for Cause. At the election of the Company for Cause (as defined
below). For the purposes of this Section 4.1, “Cause” shall mean the occuranceof any of the following: (i) the Executive’s commission of, or plea of “guilty” or “no contest” to any felony under the
laws of the United States or any state or any crime involving fraud, dishonesty or moral turpitude; (ii) the Executive’s participation in a fraud, act of dishonesty or other act of gross misconduct that adversely affect the Company;
(iii) conduct by the Executive that demonstrates the Executive’s gross unfitness to serve; (iv) the Executive’s violation of any statutory or fiduciary duty, or duty of loyalty, owed to the Company; (v) the Executive’s
material breach of any term of any contract between the Executive and the Company, including but not limited to this agreement and the Business Protection Agreement; (vi) the Executive’s material violation of any Company policy, rule or
instruction, and/or (vii) Executive’s continuing failure to perform assigned lawful duties after receiving written notification of the failure from the Company. Prior to a termination of the Executive’s employment pursuant to clause
(v) or clause (vi) above, the Executive shall have thirty (30) days to cure in all material respects such Cause event(s) (to the extent such event(s) is capable of being cured by Executive) following the Executive’s receipt of
written notice by the Company, which notice shall specifically identify the Cause upon which the termination is based and after the Executive has been given such notice. The Executive shall be considered to have been discharged for “Cause”
if (based on a final, unappealable judicial determination) the Executive has resigned from the Company without Good Reason (as defined in Section 4.3) to avoid a termination for Cause based on an event that occurred prior to such resignation
(but not an event about which the Board of Directors had actual knowledge for more than ninety (90) days prior to such resignation). Whether a termination is for Cause shall be decided by the Board in its sole and exclusive judgment and
discretion. 
 4.2 Death or Disability. Upon the death or Disability (as defined below) of the Executive. For purposes of this
Section 4.2, “Disability” means (i) the Executive has been incapacitated by mental or physical injury or illness so as to be prevented thereby from engaging in the performance of the Executive’s duties to the Company
and (ii) such incapacity has continued for a period of ninety (90) days. 
 4.3 By the Executive for Good Reason. At the
election of the Executive, for Good Reason (as defined below), provided that the Company shall have thirty (30) days to cure in all material respects such Good Reason event(s) following the Company’s receipt of the Executive’s written
notice of such Good Reason event(s). For the purposes of this Section 4.3, “Good Reason” for the Executive to terminate this employment hereunder shall mean the occurrence of any of the following events without the
Executive’s consent (unless such action is taken in response to conduct by the Executive that constitutes Cause): (i) a material reduction by the Company of the Executive’s annual base salary as initially set forth herein or as the same
may be increased from time to time, provided, however, that if such reduction occurs in connection with a Company-wide decrease in executive team compensation and then in no greater proportion than any such reduction that is applicable to the
executive team, such reduction shall not constitute Good Reason; (ii) a material breach of this Agreement by the Company; (iii) after the relocation by the Executive to the Boston, MA region following the commencement of his employment,
the subsequent relocation of the Executive’s principal place of employment, without the Executive’s consent, in a manner that lengthens Executive’s one-way commute distance by 50 or more miles
from the Executive’s then-current principal place of employment immediately prior to such relocation; or (iv) a material reduction in the Executive’s duties, authority, or responsibilities 

  
 Page 4 

 relative to thee Executive’s duties, authority, or responsibilities in effect immediately prior
to such reduction unless the Executive is performing duties and responsibilities for the Company or its successor that are similar to those the Executive was performing for the Company immediately prior to such transaction (for example, if the
Company becomes a division or unit of a larger entity and the Executive is performing duties for such division or unit that are similar to those the Executive was performing prior to such transaction but under a different title as the Executive had
prior to such transaction, there will be no “Good Reason”); provided, however that, any such termination by the Executive shall only be deemed for Good Reason pursuant to this definition if: (1) the Executive gives the Company written
notice of its intent to terminate for Good Reason within ninety (90) days following the occurrence of the condition(s) that the Executive believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails
to remedy such condition(s) within thirty (30) days following receipt of the written notice (the “Cure Period”); and (3) the Executive voluntarily terminates his employment within thirty (30) days following the end of
the Cure Period. Notwithstanding the foregoing, (A) the Executive will be deemed to have given consent to the condition(s) described in this Section 4.3 if the Executive does not provide written notice to the Company of such Good Reason
event(s) within ninety (90) days from first occurrence of such Good Reason event(s) and (B) to the extent the Company has not cured such Good Reason event(s) during the Cure Period, the Executive must terminate the Executive’s
employment for Good Reason no later than one hundred and fifty (150) days following the occurrence of such Good Reason event(s) by providing the Company thirty (30) days prior written notice of termination, which may run concurrently with
the Company’s cure period.1. 
 4.4 By the Company Not For Cause or By the
Executive Not For Good Reason. At the election of the Company for reasons other than Cause, or the election of the Executive for reasons other than Good Reason, upon not less than thirty (30) days’ prior written notice of termination.

 5. Effect of Termination. 

5.1 Payments Upon Termination. 

(a) In the event the Executive’s employment is terminated pursuant to Section 4.1, or by the Executive pursuant to Section 4.4,
the Company shall pay to the Executive the “Accrued Benefits,” which shall mean: (i) any earned but unpaid Base Salary pursuant to Section 3.1 through the last day of the Executive’s actual employment by the Company;
(ii) any unreimbursed expenses incurred through the last day of the Executive’s actual employment by the Company and reimbursable under Section 3.5; and (iii) all other payments, benefits or fringe benefits to which the Executive
shall be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant or this Agreement; but, for clarity, shall have no obligation to pay any bonus pursuant to Section 3.2.

 (b) If, and only if, the Company has consummated an equity financing pursuing to which the Company has received gross proceeds of at
least $10,000,000, then in the event the Executive’s employment is terminated pursuant to Sections 4.2, 4.3 or by the Company pursuant to Section 4.4 (including a non-renewal of this Agreement by the
Company) then the Company 
  

  
 Page 5 

 shall continue to pay to the Executive: (i) the Accrued Benefits; (ii) any annual bonus
with respect to the calendar year ending on or preceding the date of termination, which has been determined by the Board of Directors (or its Compensation Committee) prior to the date of termination pursuant to Section 3.2 but is unpaid, which
shall be payable at the time such bonuses would have been paid if the Executive was still employed with the Company and in accordance with Section 3.2; (iii) Base Salary pursuant to Section 3.1 as in effect on the date of termination
during the Severance Period (as defined below); and (iv) reimbursement for COBRA continuation medical benefits for the Executive (and the Executive’s eligible dependents) during the Severance Period. Such payments of continued salary and
any COBRA-continuation premium reimbursement shall begin on the sixtieth (60th) day after the date of termination and shall include any amounts due prior to such date. For the avoidance of doubt,
unless otherwise elected by the Board of Directors, in its sole discretion and to the extent permitted under Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including
without limitation any such regulations or other guidance that may be issued after the Effective Date, (“Section 409A”), to make payments sooner, any payments made pursuant to this Section 5.1(b) shall be
subject to the Company’s standard payroll schedule during the Severance Period. For the purposes of this Section 5.1(b), “Severance Period” means (x) during the Initial Term, the period beginning on the date of
termination and continuing afterward for the greater of (A) the balance of the Initial Term, and (B) twelve (12) months), and (y) at any time following the Initial Term, twelve (12) months. 

(c) The payments to be made or benefits to be provided to the Executive under Section 5: (i) shall be contingent upon the execution (and non-revocation) within sixty (60) days following termination of employment by the Executive of a general release of the Company, its affiliates, stockholders, directors, officers, employees and agents from all
claims (other than claims for the payments to be made and benefits to be provided), together with an agreement to not make any disparaging comments, statements or communications about the Company, its affiliates, stockholders, directors, officers,
employees or agents, or its management or business practices for three (3) years following termination of the Executive’s employment, all in a form reasonably provided by the Company; (ii) shall be contingent upon the Executive’s
compliance with all continuing obligations under the Business Protection Agreement; and (iii) shall constitute the sole remedy of the Executive in the event of a termination of the Executive’s employment in the circumstances set forth in
Section 5.1(b). 
 5.2 Section 409A. 

(a) Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to the Executive, if any,
pursuant to this Agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under Section 409A (collectively, the “Deferred Payments”) will be paid or
otherwise provided until the Executive has a “separation from service” within the meaning of Section 409A (a “Separation from Service”). 

(b) Notwithstanding anything to the contrary in this Agreement, if the Executive is a “specified employee” within the meaning of
Section 409A at the time of the Executive’s Separation from Service (other than due to death), then the Deferred Payments that are payable within the first six months following the Executive’s separation from service, will 

  
 Page 6 

 become payable on the first payroll date that occurs on or after the date six months and one day following
the date of the Executive’s separation from service. Notwithstanding anything herein to the contrary, if the Executive dies following the Executive’s separation from service, but prior to the
six-month anniversary of the separation from service, then any payments delayed in accordance with this section will be payable in a lump sum as soon as administratively practicable after the date of the
Executive’s death. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 

(c) Any amount paid under this Agreement that satisfies the requirements of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments. 
 (d) This
Agreement is intended to be exempt from the requirements of Code Section 409A so that none of the payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein
will be interpreted to be so exempt. The Company and the Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of
any additional tax or income recognition prior to actual payment to the Executive under Section 409A. 
 6.
Section 280G. 
 6.1 If any of the payments or benefits received or to be received by the Executive (including,
without limitation, any payments or benefits received in connection with a change in control or the Executive’s termination of employment, whether pursuant to the terms of this Agreement or any other plan, arrangement, or agreement, or
otherwise) (all such payments collectively referred to herein as the “280G Payments”) constitute “parachute payments” within the meaning of Section 280G of the Code and would, but for this Section 6, be subject
to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), then the Company shall cause to be determined, before any of the 280G Payments are paid to Executive, which of the following alternative forms of
payment would maximize Executive’s after-tax proceeds: (A) payment in full of the entire amount of the 280G Payment (a “Full Payment”), or 

(B) payment of only a part of the 280G Payment so that Executive receives that largest 280G Payment possible without being subject to the
Excise Tax (a “Reduced Payment”), whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax (all computed at the highest marginal rate, net of the maximum
reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in Executive’s receipt, on an after-tax basis, of the greater amount of the 280G Payment,
notwithstanding that all or some portion the 280G Payment may be subject to the Excise Tax. 
 6.2 If a Reduced Payment is required pursuant
to clause (B) of the preceding paragraph, the reduction shall occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the
same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”). 

  
 Page 7 

 6.3 Notwithstanding any provision of paragraph (a) to the contrary, if the Reduction
Method or the Pro Rata Reduction Method would result in any portion of the 280G Payment being ubject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the
Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification shall preserve
to the greatest extent possible, the greatest economic benefit for the Executive as determined on an after-tax basis; (B) as a second priority, 280G Payments that are contingent on future events (e.g.,
being terminated without cause), shall be reduced (or eliminated) before 280G Payments that are not contingent on future events; and (C) as a third priority, 280G Payments that are “deferred compensation” within the meaning of
Section 409A of the Code shall be reduced (or eliminated) before 280G Payments that are not deferred compensation within the meaning of Section 409A of the Code. 

6.4 In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Benefit as determined pursuant
to clause (B) in paragraph (a) is subject to the Excise Tax, the Executive agrees to promptly return to the Company a sufficient amount of the 280G Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the
avoidance of doubt, if the Reduced Benefit is determined pursuant to clause (A) in paragraph (a), the Executive will have no obligation to return any portion of the 280G Payment pursuant to the preceding sentence. 

6.5 The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together
with detailed supporting documentation, to the Company and Executive within thirty (30) calendar days after the date on which Executive’s right to a 280G Payment is triggered (if requested at that time by the Company or Executive) or such
other time as requested by the Company. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a 280G Payment, either before or after the application of the Reduced Amount, it shall furnish the
Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such 280G Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive
upon the Company and Executive. 
 7. Restrictive Covenants. During the Executive’s employment with the Company, the Executive
will be exposed to, and provided with, valuable confidential and/or trade secret information concerning the Company and its present and future business plans and operations. As a result, in order to protect the Company’s legitimate business
interests, the Executive shall, as a condition of commencing employment, execute and deliver to the Company the Company’s Business Protection Agreement, a copy of which is attached to this Agreement as Exhibit A, which agreement shall
contain non-competition provisions that run at least as long as the Severance Period. For clarity, the obligations and covenants of the Executive pursuant to the Proprietary Rights Agreement constitute
material responsibilities of the Executive to the Company pursuant to this Agreement. 

  
 Page 8 

 8. Other Agreements. The Executive represents that the Executive’s performance
of all the terms of this Agreement and the performance of the Executive’s duties as an employee of the Company do not and will not breach any agreement with any prior employer or other party to which the Executive is a party (including
without limitation any nondisclosure or non-competition agreement), or violate or contravene any judgment, administrative order or other legal prohibition specifically naming the Executive. The Executive
agrees that if the Executive, during the Employment Period, becomes subject to any such agreement or prohibition, the Executive shall immediately notify the Company. The Company acknowledges that it is aware that the Executive is subject to certain
confidentiality, non-competition, non-solicitation and non-disparagement covenants with respect to the Executive’s prior
employers. 
 9. Intentionally omitted. 

10. Miscellaneous. 
 10.1
Notices. Any notices delivered under this Agreement shall be deemed duly delivered four (4) business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent
for next-business day delivery via a reputable nationwide overnight courier service, in each case to the address of the recipient set forth in the introductory paragraph of this Agreement. Either party may change the address to which notices are to
be delivered by giving notice of such change to the other party in the manner set forth in this Section 10.1. 
 10.2 Pronouns.
Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 

10.3 Entire Agreement. This Agreement, together with the Stock Restriction Agreements and the Proprietary Rights Agreement, constitutes
the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement. 

10.4 Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.
The Company and the Executive agree to use commercially reasonable efforts after a Board of Directors or Compensation Committee is in place to evaluate, on a periodic basis, the terms and conditions of the Executive’s compensation and to
consider amendments to this Agreement to further define severance terms related to a change in control. 
 10.5 Interpretation, Amendment
and Enforcement. This Agreement and the Business Protection Agreement supersede and replace any prior or contemporaneous agreements, representations, communications or understandings (whether written, oral, implied or otherwise) between
Executive and the Company and constitute the complete agreement between Executive and the Company regarding the subject matter set forth herein. This letter agreement may not be amended or modified, and no breach shall be deemed to be waived, except
by an express written agreement signed by both Executive and a duly authorized officer of the Company. The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement
or arising out of, related to, or in any way connected with this letter agreement, your employment with the Company or any other relationship between Executive 

  
 Page 9 

 and the Company (a “Dispute”) will be governed by Massachusetts law, excluding laws
relating to conflicts or choice of law. Any Dispute that is commenced to resolve any matter arising under or relating to any provision of this letter agreement shall be commenced in Suffolk Superior Court of the Commonwealth of Massachusetts (or, if
appropriate, a federal court located within the Commonwealth of Massachusetts), and the Company and Executive each consent to the jurisdiction of such a court. Executive and the Company each hereby irrevocably waive any right to a trial by jury in
any Dispute arising under or relating to any provision of this letter agreement. 
 10.6 Arbitration. Any Dispute will
be settled by final and binding confidential arbitration. The arbitration will take place in Boston, Massachusetts or, at Executive’s option, the County in which you primarily worked when the arbitrable Dispute first arose. The arbitration will
be administered by JAMS under its Employment Arbitration Rules & Procedures before a single arbitrator who is a retired judge. Executive and the Company agree to provide one another with reasonable access to documents and witnesses in
connection with the resolution of the dispute. Executive and the Company will share the costs of arbitration equally. Each party will be responsible for its own attorneys’ fees, and the arbitrator may not award attorneys’ fees unless a
statute or contract at issue specifically authorizes such an award. As a material part of this agreement to arbitrate claims, both Executive and the Company expressly waive all rights to a jury trial in court on all statutory or other claims. This
agreement to arbitrate also covers any issues relating to the interpretation, applicability or enforceability of this Section 10.6. Executive also acknowledges and agrees that no claims will be arbitrated on a class action or collective action
basis. It is specifically understood and agreed that any party hereto may enforce any award rendered pursuant to the arbitration by bringing suit in any court of competent jurisdiction. Any claim must be brought to arbitration within the statute of
limitations for bringing such claim in court or before the appropriate administrative agency, as applicable. This paragraph does not apply to claims for (a) workers’ compensation benefits or unemployment insurance benefits and other claims
that cannot be arbitrated as a matter of law or (b) concerning the ownership, validity, infringement, misappropriation, disclosure, misuse or enforceability of any confidential information, patent right, copyright, mask work, trademark or any
other trade secret or intellectual property held or sought by either Executive or the Company (whether or not arising under the Business Protection Agreement between Executive and the Company). Further, notwithstanding this agreement to arbitrate,
Executive and the Company agree that either party may seek provisional remedies such as a temporary restraining order or a preliminary injunction from a court of competent jurisdiction in aid of arbitration, including, for example, provisional
remedies to enforce the restrictive covenants set forth in the Business Protection Agreement. 
 10.7 Successors and Assigns. This
Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s assets or
business, provided, however, that the obligations of the Executive are personal and shall not be assigned by the Executive. The Company may only assign this Agreement to any successor to all or substantially all of the business and/or assets
of the Company, provided that the Company shall secure such successor’s agreement to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no
such succession had taken place. As used in this Agreement, “Company” shall mean the Company and any successor to its business and/or assets, which assumes and agrees to perform the duties and obligations of the Company under this
Agreement by operation of law or otherwise. 

  
 Page 10 

 10.8 Waivers. No delay or omission by the Company or the Executive in exercising any
right under this Agreement shall operate as a waiver of that or any other right.. A waiver or consent given by the Company or the Executive on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of
any right on any other occasion. 
 10.9 No Mitigation; No Offset. In no event shall the Executive be obligated to seek other
employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement, nor shall the amount of any payment hereunder be reduced by any compensation earned by the Executive as a
result of employment by a subsequent employer. 
 10.10 Captions. The captions of the sections of this Agreement are for convenience
of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. 
 10.11
Severability. In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

10.12 Execution; Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed to be an original
but all of which together will constitute one and the same instrument. This Agreement may be executed and delivered by facsimile, email/pdf format or other electronic means and each party may fully rely upon such execution and delivery. 

10.13 Survival. The provisions of Sections 5, 6, 7, and 8 shall survive the termination of this Agreement. 

  
 Page 11 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year set forth above. 
  

	
	TDTx, INC.
	
	   /s/ Robert Johnson

	By: Robert Johnson
	Its: President
	
	EXECUTIVE
	
	 /s/ Rick Modi

	Name: Rick Modi

  
 Page 12 

 SCHEDULE 1 
  

									
	 GROSS PROCEEDS

FROM EQUITY

FINANCING
	  	SALARY TO EMPLOYEE	 	  	BONUS OPPORTUNITY	 

	 >$3.0 MILLION
	  	$	100,000.00	 	  	$	50,000.00	 
	 >$5.0 MILLION
	  	$	250,000.00	 	  	$	125,000.00	 
	 >$10.0 MILLION
	  	$	425,000.00	 	  	$	212,500.00	 

  
 Page 13 

 EXHIBIT A 

Proprietary Rights Agreement 

  
 Page 14 

 EXHIBIT B 

USCIS Form I-9 

  
 Page 15EX-10.12

 Exhibit 10.12 

 
 

 
 Affinia Therapeutics Inc. 

100 Beaver Street 
 Waltham, MA 

02453 
 December 4, 2020 

Charles Albright, Ph.D. 
 160 Beacon St., Unit 8. 

Boston, MA 02116 
 Dear Charles: 

Affinia Therapeutics Inc. (the “Company”) is pleased to offer you employment on the following terms: 

1. Position. Your employment will be effective as of January 18, 2021 (the “Effective
Date”). Your initial title will be Chief Scientific Officer, and you will initially report to the Company’s Chief Executive Officer (“CEO”). This is a full-time position pursuant to which you will devote substantially
all of your business time, attention and energies to the tasks and duties of your position as assigned by the Company. At all times you will be expected to abide by all policies and procedures of the Company as in effect from time to time. While you
are employed by the Company, you will not engage in any other employment, consulting or other business activity that would create a conflict of interest with the Company. During your employment with the Company, you will be permitted to participate
as a member of up to three (3) Boards of Directors or Advisory positions, provided that you obtain the prior written consent of the Company for each Scientific Advisory Board that you are a member of, and provided further that your activities
in relation thereto are not in violation of any of your obligations to Company under the Business Protection Agreement, which is attached hereto and incorporated by reference as Exhibit A. By signing this letter agreement (the “Offer
Letter”), you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company. 

2. Cash Compensation. 

(a) Signing Bonus. You shall be advanced, within 30 (thirty) days of the Effective Date, a signing and retention bonus in the amount of
$100,000.00, less applicable deductions and withholdings (the “Signing Bonus”), which will be earned in full on the twelve (12)-month anniversary of the Effective Date. If you resign without Good Reason (as defined below) or are
terminated for Cause (as defined below) before the twelve (12)-month anniversary of the Effective Date, you shall be obligated to, and hereby agree to, repay a prorated portion of the net, after-tax amount of
the Signing Bonus based on the number of days you were employed by the Company prior to your resignation without Good Reason or termination for Cause. You agree that if you are obligated to repay the Signing Bonus, the Company may deduct, in
accordance with applicable law, such amount from any payments the Company owes you, including but not limited to any regular payroll amount and any expense payments. You further agree to pay to the Company, within sixty (60) days of the
effective termination date, any remaining unpaid balance of the unearned Signing Bonus not covered by such deductions. 

 C. Albright 

December 4, 2020 
  Page
 2
 
  

 (b) Base Salary. The Company will pay you an initial annualized salary of $415,000.00,
payable in accordance with the Company’s standard payroll schedule and subject to required tax withholding and other authorized deductions (the “Base Salary”). No period of employment is implied by such payment period, nor
shall it alter the “at will” nature of your employment as described below and herein. This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time. 

(c) Annual Bonus. In addition to your Base Salary, you will be eligible to be considered for an annual incentive cash bonus as described
below (the “Annual Bonus”). The Annual Bonus (if any) will be awarded based on objective and/or subjective criteria established by the Company’s CEO and be subject to the approval of the Company’s Board of Directors (the
“Board”). Your target Annual Bonus shall be thirty-five percent (35%) of your then-current Base Salary (the “Target Bonus”). You will be paid the full Target Bonus for Fiscal Year 2020. Any Annual Bonus for a fiscal
year will be paid within 21⁄2 months after the close of that fiscal year, but will be contingent upon your continued employment through the applicable payment date.
You hereby acknowledge and agree that nothing contained herein confers upon you any right to an Annual Bonus in any year, and that whether the Company pays you an Annual Bonus and the amount of any such Annual Bonus will be determined by the Company
in its sole discretion. 
 3. Employee Benefits. As a regular employee of the Company, you will be eligible to
participate in Company-sponsored benefit plans made available by the Company from time to time to employees generally, subject to plan terms and generally applicable Company policies. In addition, you will initially be entitled to accrue paid
vacation of 20 days annually and consistent with the Company’s employee benefits policy in addition to customary business holidays approved by the Board for the Company’s employees generally, and the Company’s sick leave policy, in
accordance with applicable law and Company policy, as in effect from time to time. 
 4. Equity. In connection with
entering into this Offer Letter and as mutually agreed upon consideration for your undertaking the obligations set forth in Sections 4.2 and 4.3 of the Invention Assignment, Non-Disclosure, and Business
Protection Agreement attached hereto as Exhibit A (the “Business Protection Agreement”), it will be recommended at the first meeting of the Board following your employment start date, which meeting shall take place no later than
forty-five (45) days after the Effective Date, that the Company grant you options to purchase Common Stock of the Company as described below, at a price per share equal to the fair market value per share of the Common Stock on the date of
grant, as determined by the Board. 
 (a) Welcome Grant. An option to purchase 470,000 shares of the Company’s Common Stock (the
“Welcome Grant”). Twenty five percent (25%) of the shares subject to the Welcome Grant will vest 12 months after the date your employment begins, subject to your continuing employment with the Company, and no shares will vest before
such date. The remaining shares will vest monthly over the next 36 months in equal monthly amounts, subject to your continuing employment with the Company. 

(b) T2 Grant. An option to purchase 176,000 shares of the Company’s Common Stock (the “T2 Grant”). Twenty five
percent (25%) of the shares subject to the T2 Grant will vest on the date that is 12 months after the date of the closing of the second tranche of the Company’s Series A financing, subject to your continuing employment with the Company, and no
shares will vest before such date. The remaining shares will vest monthly over the next 36 months in equal monthly amounts, subject to your continuing employment with the Company. If the closing of the second tranche of the Company does not take
place by December 31, 2021, the T2 Grant will automatically terminate with no shares having vested. 

 C. Albright 

December 4, 2020 
  Page
 3
 
  

 (c) General Terms. Both the Welcome Grant and the T2 Grant will be subject to the
terms and conditions of the Company’s Stock Option Plan and Stock Option Agreement, including vesting requirements and this Agreement. No right to any stock is earned or accrued until such time that vesting occurs, nor does the grant confer any
right to continue vesting or employment. 
 5. Termination of Employment. The parties acknowledge that your
employment with the Company is for no specific period of time. Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without notice
or Cause. Any contrary representations that may have been made to you are superseded by this Offer Letter. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits,
as well as the Company’s personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the
Company (other than you). The provisions of this Section 5 govern the amount of compensation, if any, to be provided to you upon termination of employment and do not alter this at-will status. 

(a) Termination for Cause or Due to Your Death, Disability or Resignation without Good Reason. If, at any time, the Company terminates
your employment for Cause (as defined below), or if either party terminates your employment as a result of your death or Disability (as defined below), or you resign without Good Reason (as defined below), you will receive the following
“Accrued Benefits”: (i) any earned but unpaid Base Salary through the date of termination and any accrued but unused vacation through the date of termination; (ii) any unreimbursed business expenses incurred by you payable in
accordance with the Company’s standard expense reimbursement policies; and (iii) all other payments, benefits or fringe benefits to which you shall be entitled under the terms of any applicable compensation arrangement or benefit, equity
or fringe benefit plan or program or grant or this Offer Letter; but, for clarity, the Company shall have no obligation to pay you any bonus pursuant to Section 2(c). Under these circumstances, you will not be entitled to any other form of
compensation from the Company, including any severance benefits. For purposes of this Offer Letter, “Disability” means (i) you have been incapacitated by mental or physical injury or illness so as to be prevented thereby from
engaging in the performance of your duties, with or without a reasonable accommodation as required by law to the Company and (ii) such incapacity has continued for a period of one-hundred and eighty
(180) consecutive days. 
 (b) Termination without Cause or Resignation with Good Reason not in Connection with a Change in
Control. If the Company terminates your employment without Cause (as defined below) or you resign from employment with Good Reason (as defined below) not in connection with a Change in Control (as defined in the Plan), and provided such
termination constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from
Service”), then in addition to receiving the Accrued Benefits, and subject to your compliance with the obligations in Section 5(b)(iii) below, you shall receive the following “Severance Benefits”: 

(i) An amount equal to the equivalent of your then current base salary for nine (9) months on the schedule described below in
Section 5(d); and 

 C. Albright 

December 4, 2020 
  Page
 4
 
  

 (ii) Provided you or your covered dependents, as the case may be, timely elect continued
coverage under COBRA under the Company’s group health and dental plans following such termination, the COBRA premiums to continue your (and your covered dependents, as applicable) health insurance coverage in effect on the termination date
until the earliest of: (1) nine (9) months after the termination date; (2) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment; or (3) the date
you cease to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the termination date through the earlier of (1)-(3), the “COBRA Payment Period”). Notwithstanding the foregoing,
if at any time the Company determines that its payment of COBRA premiums on your behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health
Care and Education Reconciliation Act), then in lieu of paying COBRA premiums pursuant to this Section, the Company shall pay you on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA
premium for such month, subject to applicable tax withholding, for the remainder of the COBRA Payment Period. Nothing in this Offer Letter shall deprive you of your rights under COBRA or ERISA for benefits under plans and policies arising under your
employment by the Company. 
 (iii) Condition of Severance Benefits. Your receipt of Severance Benefits is conditional upon
(i) your continuing to comply with your obligations under your Business Protection Agreement; (ii) your timely execution and non-revocation of a separation agreement with the Company containing a
general release of claims in favor of the Company and its affiliates in the form presented by the Company no later than your last date of employment, which shall include a non-disparagement and non-competition clause (and which is executed and allowed to become effective within the consideration period provided in the separation agreement, which in no event shall be later than the 60th day following your Separation from Service) (the “Separation Agreement”); and (iii) your complying with all terms of the Separation Agreement, including but not limited to any
confidentiality, non-disparagement, non-competition and return of company property provisions. The salary continuation will be paid in equal installments on the
Company’s regular payroll schedule and will be subject to applicable tax withholdings over the period outlined above following the date of your termination; provided, however, that no payments will be made prior to the 8th day following the effective date of the release contained in the Separation Agreement. 

(c) Termination without Cause or Resignation with Good Reason in Connection with a Change in Control. In the event that the Company
terminates your employment without Cause or you resign for Good Reason on or within twelve (12) months following the effective date of a Change in Control (such termination date the “Change in Control Termination Date”), then
you shall be entitled to the Accrued Benefits and, subject to your compliance with Section 5(b)(iii) above, including but not limited to the release requirement and your continued compliance with your obligations to the Company under your
Business Protection Agreement, then you will be eligible to receive (i) the Severance Benefits set forth in Section 5(b) above, and (ii) effective as of the later of your Change in Control Termination Date or the effective date of the
Change in Control, the vesting and exercisability of all outstanding equity awards that are held by you as of immediately prior to the Change in Control Termination Date shall be accelerated (and lapse, in the case of reacquisition or repurchase
rights) in full. 
 (d) Definition of Cause. For purposes of this Offer Letter, “Cause” shall mean the occurrence of
any of the following: (i) your commission of, or plea of “guilty” or “no contest” to any felony under the laws of the United States or any state or any crime involving fraud, dishonesty or moral turpitude; (ii) your
participation in a fraud, act of dishonesty or other act of gross misconduct that adversely affect the Company; (iii) conduct by you that demonstrates your gross unfitness to serve; (iv) your violation of any statutory or fiduciary duty,
or duty of loyalty, owed to the Company; (v) your material breach of any term of any contract between you and the Company, including but not limited to this agreement and the Business Protection Agreement; (vi) your material violation of
any Company policy, rule or instruction, and/or (vii) your continuing failure to perform assigned lawful duties after receiving written notification of the failure from the Company. Prior to a termination of your employment pursuant to clause
(v) or clause (vi) above, you shall have thirty (30) days to cure in all material respects such Cause event(s) (to the extent such event(s) is capable of being cured by you) following your receipt of written notice by the Company,
which notice shall specifically identify the Cause upon which the termination is based and after you have been given such notice. Whether a termination is for Cause shall be decided by the Board in its sole and exclusive judgment and discretion.

 C. Albright 

December 4, 2020 
  Page
 5
 
  

 (e) Definition of Good Reason. For the purposes of this Offer Letter, “Good
Reason” for you to terminate your employment hereunder shall mean the occurrence of any of the following events without your consent (unless such action is taken in response to conduct by you that constitutes Cause): (i) a material
reduction by the Company of your annual base salary as initially set forth herein or as the same may be increased from time to time, provided, however, that if such reduction occurs in connection with a Company-wide decrease in executive team
compensation and then in no greater proportion than any such reduction that is applicable to the executive team, such reduction shall not constitute Good Reason; (ii) a material breach of this Offer Letter by the Company; (iii) the
relocation of your principal place of employment, without your consent, in a manner that lengthens your one-way commute distance by 50 or more miles from your then-current principal place of employment
immediately prior to such relocation; or (iv) a material reduction in your duties, authority, or responsibilities relative to your duties, authority, or responsibilities in effect immediately prior to such reduction unless you are performing
duties and responsibilities for the Company or its successor that are similar to those you were performing for the Company immediately prior to such transaction (for example, if the Company becomes a division or unit of a larger entity and you are
performing duties for such division or unit that are similar to those you were performing prior to such transaction but under a different title as you had prior to such transaction, there will be no “Good Reason”); provided, however that,
any such termination by you shall only be deemed for Good Reason pursuant to this definition if: (1) you give the Company written notice of your intent to terminate for Good Reason within thirty (30) days following the occurrence of the
condition(s) that you believe constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the “Cure
Period”); and (3) you voluntarily terminate your employment within thirty (30) days following the end of the Cure Period. Notwithstanding the foregoing, (A) you will be deemed to have given consent to the condition(s) described in
this Section 5(e) if you do not provide written notice to the Company of such Good Reason event(s) within thirty (30) days from first occurrence of such Good Reason event(s) and (B) to the extent the Company has not cured such Good
Reason event(s) during the Cure Period, you must terminate your employment for Good Reason no later than thirty (30) days following the end of the Cure Period. 

(f) Cooperation With the Company After Termination of Employment. Following termination of your employment for any reason, you shall
reasonably cooperate with the Company in all matters relating to the winding up of your pending work including, but not limited to, any litigation in which the Company is involved, and the orderly transfer of any such pending work to such other
executives as may be designated by the Company; provided, that the Company agrees that the Company (a) shall make reasonable efforts to minimize disruption of your other activities, and (b) shall reimburse you for all reasonable expenses
incurred in connection with such cooperation. 
 (g) Effect of Termination. You agree that should your employment be terminated for
any reason, you shall be deemed to have resigned from any and all positions with the Company, including, but not limited to, a position on the Board and all positions with any and all subsidiaries and affiliates of the Company. 

6. Section 409A. It is intended that all payments and benefits under this Offer Letter shall either comply with or
be exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and other guidance thereunder and any ambiguity contained herein shall be interpreted in such manner so as to avoid adverse
personal tax consequences under Section 409A. For purposes of applying the provisions of Section 409A to this Agreement, each separately identified amount to which Executive is entitled under this Agreement shall be treated as a separate
payment. In addition, to the extent permissible under Section 409A, any series of installment payments under this Agreement shall be treated as a right to a series of separate payments. 

 C. Albright 

December 4, 2020 
  Page
 6
 
  

 7. Certain Conditions. Like all Company employees, as a condition
of employment with the Company, you will be required (a) to sign the Company’s standard Business Protection Agreement, a copy of which is attached hereto as Exhibit A, which among other things, prohibits unauthorized use or
disclosure of Company proprietary information; (b) to sign and return a satisfactory USCIS Form I-9 attached hereto as Exhibit B and provide sufficient documentation when you report to work
establishing your employment eligibility in the United States of America as required by law (enclosed is a list of acceptable Form I-9 documentation); and (c) to provide satisfactory proof of your
identity as required by law. 
 8. Tax Matters. 

(a) Withholding. All forms of compensation referred to in this Offer Letter are subject to reduction to reflect applicable withholding
and payroll taxes and other deductions required by law. 
 (b) Tax Advice. You are encouraged to obtain your own tax advice regarding
your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board related to tax
liabilities arising from your compensation. 
 9. Interpretation, Amendment and Enforcement. This Offer Letter
and Exhibit A supersede and replace any prior or contemporaneous agreements, representations, communications or understandings (whether written, oral, implied or otherwise) between you and the Company and constitute the complete agreement
between you and the Company regarding the subject matter set forth herein. This Offer Letter may not be amended or modified, and no breach shall be deemed to be waived, except by an express written agreement signed by both you and a duly authorized
officer of the Company. The terms of this Offer Letter and the resolution of any disputes, in law or equity, including but not limited to statutory claims (including, but not limited to, the Massachusetts Antidiscrimination Act, Mass. Gen. Laws
ch.151B and the Massachusetts Wage Act, Mass. Gen. Laws ch. 149), as to the meaning, effect, performance or validity of this Offer Letter or arising out of, related to, or in any way connected with, this Offer Letter, your employment with the
Company or any other relationship between you and the Company, (a “Dispute”) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of law. You and the Company each hereby irrevocably waive any right
to a trial by jury in any Dispute arising under or relating to any provision of this Offer Letter. 

 C. Albright 

December 4, 2020 
  Page
 7
 
  

 10. Arbitration. Any Dispute will be settled by final and binding
confidential arbitration. The arbitration will take place in Boston, Massachusetts or, at your option, the County in which you primarily worked when the arbitrable Dispute first arose. The arbitration will be administered by JAMS under its
Employment Arbitration Rules & Procedures before a single arbitrator who is a retired judge. You and the Company agree to provide one another with reasonable access to documents and witnesses in connection with the resolution of the
dispute. You and the Company will share the costs of arbitration equally. Each party will be responsible for its own attorneys’ fees, and the arbitrator may not award attorneys’ fees unless a statute or contract at issue specifically
authorizes such an award. As a material part of this agreement to arbitrate claims, both you and the Company expressly waive all rights to a jury trial in court on all statutory or other claims. This agreement to arbitrate also covers any issues
relating to the interpretation, applicability or enforceability of this Section 10. You also acknowledge and agree that no claims will be arbitrated on a class action or collective action basis. It is specifically understood and agreed that any
party hereto may enforce any award rendered pursuant to the arbitration by bringing suit in any court of competent jurisdiction. Any claim must be brought to arbitration within the statute of limitations for bringing such claim in court or before
the appropriate administrative agency, as applicable. This paragraph does not apply to claims for (a) workers’ compensation benefits or unemployment insurance benefits and other claims that cannot be arbitrated as a matter of law or
(b) concerning the ownership, validity, infringement, misappropriation, disclosure, misuse or enforceability of any confidential information, patent right, copyright, mask work, trademark or any other trade secret or intellectual property held
or sought by either you or the Company (whether or not arising under the Business Protection Agreement between you and the Company) (“Excluded Claims”). Any Dispute that is commenced to resolve any matter relating to Excluded Claims
shall be commenced in Suffolk Superior Court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within the Commonwealth of Massachusetts), and the Company and you each consent to the jurisdiction of such a court.
Further, notwithstanding this agreement to arbitrate, you and the Company agree that either party may seek provisional remedies such as a temporary restraining order or a preliminary injunction from such a court in aid of arbitration, including, for
example, provisional remedies to enforce the restrictive covenants set forth in the Business Protection Agreement. 
 ***** 

 

 
 Affinia Therapeutics Inc. 

100 Beaver Street 
 Waltham, MA 

02453 
 We hope that you will
accept our offer to join the Company. You may indicate your agreement with these terms and accept this offer by signing and dating both this Offer Letter and the enclosed Business Protection Agreement and returning them to me. This offer, if not
accepted, will expire at the close of business on December 22, 2020. As required by law, your employment with the Company is contingent upon your providing legal proof of your identity and authorization to work in the United States. Please
retain a copy of this Offer Letter and Business Protection Agreement for your records. Your employment is also contingent upon your starting work with the Company on or before January 18, 2021. This letter is binding on the Company’s
successors and assigns. 
 If you have any questions, please call me. 

 

			
	Very truly yours,
	
	AFFINIA THERAPEUTICS INC.
		
	By:	 	 /s/ Rick Modi

	Name:	 	Rick Modi
	Title:	 	Chief Executive Officer

 I have read and accept this employment offer: 
  

	
	 /s/ Charles Albright

	Signature of Employee

 Dated: 12/20/2020 

Attachment 
 Exhibit A: Invention Assignment, Non-Disclosure, and Business Protection Agreement 
 Exhibit B: USCIS I-9 

 C. Albright 

December 4, 2020 
  Page
 9
 
  

 EXHIBIT A 

THIS INVENTION ASSIGNMENT, NON-DISCLOSURE, AND BUSINESS PROTECTION AGREEMENT (the “Agreement”)
is made by and between Affinia Therapeutics Inc., a Delaware corporation with an office at 100 Beaver Street, Waltham, MA, 02453 (the “Company” or “Affinia Therapeutics”) and Charles Albright, Ph.D., with an
address at 160 Beacon St., Unit 8, Boston, MA 02116 (“Employee”). 
 The Company and Employee agree as follows: 

 

	1.	 Condition of Employment. Employee acknowledges that protection of the
Company’s proprietary and confidential information is critical to the survival and success of the Company’s business because of the nature of the Company’s business. This Agreement is intended to protect the Company’s business
(including that of its subsidiaries and affiliates) without unreasonably restricting Employee’s ability to work elsewhere if his/her employment with the Company ends. This Agreement will become effective on the earliest of: (a) the date of
Employee’s signature below, (b) the first day of Employee’s employment by the Company, or (c) the first day on which the Company discloses Proprietary Information to Employee. Subject to paragraph 4.6, Employee’s obligations
under this Agreement will continue even after his/her employment with the Company has ended, whether in circumstances of voluntary or involuntary termination of employment, and regardless of whether additional severance compensation is paid by the
Company. 

  

	2.	 Proprietary and Confidential Information. 

 

	 	2.1	 Employee agrees that all non-public information and know-how, whether or not in writing, of a private, secret or confidential nature, relating to the Company’s (including its subsidiaries’ and affiliates’) actual or anticipated business, products,
interests, research and development or financial affairs (collectively, “Proprietary Information”) encountered by Employee in the course of or as a result of his/her relationship with the Company is and shall be the exclusive
property of the Company. By way of illustration, but not limitation, Proprietary Information may include discoveries, inventions, products, product improvements, product enhancements, processes, methods, techniques, formulas, compositions,
compounds, negotiation strategies and positions, projects, developments, plans (including business and marketing plans), research data, clinical data, financial data (including sales costs, profits, pricing methods), personnel data, computer
programs (including software used pursuant to a license agreement), customer, prospect and supplier lists, and contacts at or knowledge of customers or prospective customers of the Company, and shall include Developments, as defined below. Employee
will not disclose any Proprietary Information to any person or entity other than employees of the Company or use the same for any purposes (other than in the performance of his/her duties as an employee of the Company) without written approval by an
officer of the Company, either during or after his/her employment with the Company, unless and until such Proprietary Information has become public knowledge through voluntary public disclosure by someone who had the right to make such a disclosure.
While employed by the Company, Employee will use Employee’s best efforts to prevent unauthorized use, publication or disclosure of any of the Company’s Proprietary Information. 

  
 Page 9 of 18 

 C. Albright 

December 4, 2020 
  Page
 10
 
  

	 	2.2	 Employee agrees that all files, documents, letters, memoranda, reports, records, data, sketches, drawings,
models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible or intangible material containing Proprietary Information, whether created by Employee or others,
which shall come into his/her custody or possession, shall be and are the exclusive property of the Company (or any person or entity designated by the Company) to be used by Employee only in the performance of his/her duties for the Company and
shall not be copied or removed from the Company premises except in the reasonable pursuit of the business of the Company. All such materials or copies of such materials and all tangible property of the Company in the custody or possession of
Employee shall be delivered to the Company, upon the earlier of (a) a request by the Company or (b) termination of his/her employment. After such delivery, Employee shall not retain any such materials or copies of such materials, including
but not limited to electronic copies, or any such tangible property. Employee also agrees to disclose to the Company, upon the earlier of a request by the Company or termination of his/her employment, all passwords necessary or desirable to obtain
access to, or that would assist in obtaining access to, any information which Employee has password-protected on any computer equipment, network or system of the Company. 

 

	 	2.3	 Employee agrees that his/her obligation not to disclose or to use information and materials of the types set
forth in paragraphs 2.1 and 2.2 above, and his/her obligation to return materials and tangible property, set forth in paragraph 2.2 above, also extends to such types of information, materials and tangible property encountered by Employee in the
course of or as a result of his/her relationship with the Company or customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted such information and materials to the Company or to Employee.

  

	 	2.4	 However, in the event that Employee (a) is required, by court or administrative or regulatory order, or
any governmental regulator with jurisdiction over Employee, to disclose any portion of the Proprietary Information or (b) is asked to or seeks to enter into evidence or otherwise voluntarily disclose in any administrative, judicial,
quasi-judicial or arbitral proceeding, any portion of the Proprietary Information, Employee shall provide the Company with prompt written notice of any such request or requirement prior to the disclosure of Proprietary Information, so the Company
may, at the Company’s expense, seek a protective order or other appropriate remedy to prohibit or to limit such disclosure. If, in the absence of a protective order, Employee is nonetheless compelled to disclose any Proprietary Information,
Employee shall as soon as practicable thereafter advise the Company of the Proprietary Information so disclosed and the persons to whom it was so disclosed, and thereafter, may disclose only such portions of the Proprietary Information that are
legally required to be disclosed. 

  

	 	2.5	 The Company provides notice to Employee that pursuant to the United States Defend Trade Secrets Act of 2016:

  

	 	(a)	 An individual will not be held criminally or civilly liable under any United States federal or state trade
secret law for the disclosure of a trade secret that is made (i) in confidence to a federal, state, or local government official or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or
(ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and 

  
 Page 10 of 18 

 C. Albright 

December 4, 2020 
  Page
 11
 
  

	 	(b)	 An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may
disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (i) files any document containing the trade secret under seal; and (ii) does not disclose the trade
secret, except pursuant to court order. 

  

	 	2.6	 In addition, this Agreement does not prohibit Employee from participating in or cooperating with any government
investigation or proceeding, nor does this Agreement restrict Employee from disclosing Proprietary Information to government agencies in a reasonable manner when permitted by applicable state or federal “whistleblower” or other laws.

  

	3.	 Developments. 

 

	 	3.1	 Employee will, except as expressly provided in paragraph 3.4, make full and prompt disclosure to the Company
of: all discoveries, inventions, improvements, enhancements, processes, methods, techniques, developments, software, and works of authorship, whether patentable or not, (a) which have been created, made, conceived or reduced to practice by
Employee or under his/her direction or jointly with others prior to the date hereof and which are potentially competitive with, or relate directly or indirectly to, Affinia Therapeutics’ (including its subsidiaries’ and affiliates’)
actual or anticipated business, products, interests or research and development, (b) which are created, made, conceived or reduced to practice by him/her or under his/her direction or jointly with others during his/her employment by Affinia
Therapeutics, whether or not during normal working hours or on the premises of the Company, or (c) which are created, made, conceived or reduced to practice by him/her or under his/her direction or jointly with others using or based on
knowledge of the Company’s tools, devices, equipment or Proprietary Information (all of which are collectively referred to in this Agreement as “Developments”). 

 

	 	3.2	 Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the
Company) all his/her right, title and interest in and to all Developments and all related patents, patent applications, copyrights and copyright applications. However, this paragraph 3.2 shall not apply to Developments (described in clauses 3.1(b)
and 3.1(c) above) which are not potentially competitive with, and do not relate directly or indirectly to, the Company’s (including its subsidiaries’ and affiliates’) actual or anticipated business, products, interests or research and
development at the time such Development is created, made, conceived or reduced to practice, and which are made and conceived by Employee not during normal working hours, not on the Company’s premises and not using or based on knowledge of the
Company’s tools, devices, equipment or Proprietary Information. Employee understands that, to the extent this Agreement shall be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign
certain classes of inventions made by an employee, this paragraph 3.2 shall be interpreted not to apply to any invention which a court rules and/or the Company agrees falls within such classes. Employee also hereby waives all claims to moral rights
in any Developments. 

  
 Page 11 of 18 

 C. Albright 

December 4, 2020 
  Page
 12
 
  

	 	3.3	 All discoveries, inventions, improvements, enhancements, processes, methods, techniques, developments,
software, and works of authorship, whether patentable or not, arising in the one year period after the termination or cessation of such employment for any reason which (i) are potentially competitive with, or relate directly or indirectly to,
the Company’s (including its subsidiaries’ and affiliates’) actual or anticipated business, products, interests or research and development, and (ii) relate to any patent, copyright, trade secret, or other intellectual property
right, worked on by Employee while Employee is employed by the Company, shall be presumed to have been created, made, conceived or reduced to practice during Employee’s employment with the Company and shall therefore be deemed a Development;
provided, however, that Employee may overcome the presumption with respect to the period of one year after the termination or cessation of employment by proving that such creation, making, conception or reduction to practice occurred
exclusively following employment with the Company and without use of, and not based on knowledge of, the Company’s tools, devices, equipment or Proprietary Information. 

 

	 	3.4	 To preclude any possible uncertainty concerning the ownership of Developments, Employee agrees to provide to
the Company a complete written list of any Developments that Employee considers to be his/her property or the property of a third party and that Employee and the Company agree shall be excluded from the scope of this Agreement (“Prior
Inventions”). If disclosure of any Prior Invention would cause Employee to violate any prior confidentiality agreement, Employee understands that Employee is not to fully describe such Prior Inventions, but is only to disclose a cursory
name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such invention has not been made for that reason. Employee shall also list all patents and patent applications in which Employee is
named as an inventor, other than those which have been assigned to the Company. If no such disclosure is provided on or before the start of Employee’s employment by the Company, Employee represents that there are no Prior Inventions.

  

	 	3.5	 Employee agrees to cooperate fully with the Company (or any person or entity designated by the Company), both
during and after his/her employment with the Company, with respect to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States and foreign countries) relating to
Developments. Employee shall sign all papers, including, without limitation, copyright applications, patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company (or any
person or entity designated by the Company) may deem necessary or desirable in order to protect its rights and interests in any Development. Employee further agrees that if the Company (or any person or entity designated by the Company) is unable,
after reasonable effort, to secure the signature of Employee on any such papers, the Company and its duly authorized officers and designees shall be entitled to execute any such papers as the agent and the attorney-in-fact of Employee, and Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and designees as his/her agent and attorney-in-fact to execute any such papers on his/her behalf, and to take any and all actions as may be deemed necessary or desirable in order to protect the Company’s or its designees’ rights and
interests in any Development, under the conditions described in this sentence. 

  
 Page 12 of 18 

 C. Albright 

December 4, 2020 
  Page
 13
 
  

	4.	 Non-Competition. 

 

	 	4.1	 Non-Competition During Employment. While Employee is employed by
the Company, Employee will not directly or indirectly, engage or assist others in engaging in any Competing Organization (whether as owner, partner, officer, director, employee, consultant, investor, lender or otherwise, except as the holder of not
more than 1% of the outstanding stock of a publicly-held company). The term “Competing Organization” means any person, entity or organization engaged in, or anticipated to become engaged in, research on or the acquisition,
development, production, distribution, marketing, or providing of a product, process or service that competes or is reasonably expected to compete with a material product, process or service in existence or being developed or anticipated to be
developed by the Company. 

  

	 	4.2	 Restrictions on Competition Post-Employment. For a period of twelve (12) months following the
termination of Employee’s employment with the Company (the “Restricted Period”), Employee will not Compete with the Company. The term “Compete” means providing to a Competing Organization the same types of
services (whether as owner, partner, officer, director, employee, consultant, investor, lender or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held company) that Employee provided to the Company in any
geographic areas in which Employee provided services or had a material presence or influence, directly or indirectly, at any time within the last two (2) years of employment. 

 

	 	4.3	 Extension and Tolling of Restricted Period. The Restricted Period in paragraph 4.2 shall automatically
extend from twelve (12) months to twenty-four (24) months after termination of Employee’s employment in the event that Employee (a) breaches a fiduciary duty to the Company, or (b) unlawfully takes, physically or
electronically, property belonging to the Company. In addition, if Employee violates paragraph 4.2, Employee shall continue to be bound by its restrictions until a period of twelve (12) months has expired without any violation of such
provisions. 

  

	 	4.4	 Mutually Agreed Upon Consideration. Employee and the Company mutually agree that Employee’s
eligibility to (a) be issued an option or options to purchase shares of the Company’s Common Stock pursuant to the terms of the Employee’s offer letter and a corresponding option grant agreement by and between Employee and the Company
and (b) receive a discretionary bonus as set forth in Employee’s offer letter (collectively, the “Mutually Agreed Upon Consideration”) shall be contingent on Employee’s agreement to the noncompetition restrictions set
forth in paragraphs 4.2 and 4.3 of this Agreement. Unless and until Employee agrees to those restrictions, Employee shall not be permitted to receive the Mutually Agreed Upon Consideration, which Employee acknowledges and agrees is fair, reasonable,
and adequate to support the noncompetition restrictions set forth in paragraphs 4.2 and 4.3. 

  

	 	4.5	 Non-Competitive Divisions. Paragraphs 2.1 and 4.2 shall not
preclude Employee from, after the cessation of employment with the Company, becoming an employee of, consultant to, or from otherwise providing services to, a separate division or operating unit of a multi-divisional business or enterprise (a
“Division”) if (a) the Division by which Employee is employed or engaged, or to which Employee provides services, is not (if treated by itself as an independent entity) a Competing Organization, (b) Employee does not
provide services, directly or indirectly, to any other division or operating unit of such multi-divisional business or enterprise that is a Competing Organization (if treated by itself as an independent entity) (individually, a “Competitive
Division” and collectively, the “Competitive Divisions”) and (c) the Competitive Divisions, in the aggregate, accounted for less than one-third of the multi-divisional business
or enterprise’s consolidated revenues for the fiscal year, and each subsequent quarterly period, prior to Employee’s commencement of employment with the Division. 

  
 Page 13 of 18 

 C. Albright 

December 4, 2020 
  Page
 14
 
  

	 	4.6	 Terminations without Cause and Layoffs. To the extent required by law, the Company shall not enforce
paragraph 4.2 in the event that Employee is terminated without cause or laid off, unless it is discovered that Employee took the Company’s information and/or violated a fiduciary duty. Solely for the purposes of this Agreement, Employee agrees
that the following shall constitute grounds for a termination for cause: (a) a reasonable basis for the Company’s dissatisfaction with Employee, entertained in good faith, for reasons such as lack of capacity or diligence, failure to
conform to usual standards of conduct, or other culpable or inappropriate behavior, or (b) grounds for discharge reasonably related, in the Company’s honest judgment, to the needs of its business. A termination is not for cause if it is on
unreasonable grounds or arbitrarily, capriciously, or in bad faith. For purposes of clarity, the above described grounds for a termination for cause shall be applicable only to this Agreement, and not any other agreement entered into between
Employee and the Company related to employment, equity or otherwise that contains or uses the terms “Cause” or “cause”. 

  

	 	4.7	 Acknowledgments. Employee acknowledges that the noncompetition restrictions in paragraphs 4.1 and 4.2
are no broader than necessary to protect the Company’s interests in its trade secrets, confidential information, and/or goodwill. Employee further acknowledges that these noncompetition restrictions cannot be adequately protected through an
alternative restrictive covenant, including but not limited to a non-solicitation agreement or a non-disclosure or confidentiality agreement. 

 

	5.	 Non-Solicitation. While Employee is employed by
the Company and for a period of one (1) year after the termination or cessation of such employment for any reason (the “Non-Solicitation Period”), Employee will not directly or
indirectly: 

  

	 	5.1	 Either alone or in association with others, solicit, divert or take away, or attempt to divert or take away,
the business or patronage of any of the clients, customers, or business partners of the Company that were contacted, solicited, or served by Employee directly or the Company during the 12-month period prior to
the termination or cessation of Employee’s employment with the Company; or 

  

	 	5.2	 Either alone or in association with others (a) solicit, induce or attempt to induce, any employee or
independent contractor of the Company to terminate his or her employment or other engagement with the Company, or (b) hire, or recruit or attempt to hire, or engage or attempt to engage as an independent contractor, any person who was employed
or otherwise engaged by the Company at any time during the term of Employee’s employment with the Company; provided, that this clause (b) shall not apply to the recruitment or hiring or other engagement of any individual whose
employment or other engagement with the Company has been terminated for a period of six months or longer. However, this paragraph 5.2 shall not apply to (x) general advertising or solicitation not specifically targeted at the Company, its
employees or independent contractors, (y) Employee serving as a reference, upon request, for any employee or independent contractor of the Company, and (z) actions taken by any person or entity with which Employee is associated if Employee
is not personally involved in any manner in the hiring, recruitment, solicitation or engagement of any such individual (including but not limited to identifying any such individual for hiring, recruitment, solicitation or engagement).

  
 Page 14 of 18 

 C. Albright 

December 4, 2020 
  Page
 15
 
  

	 	5.3	 So that the Company may enjoy the full benefit of the covenants contained in this paragraph 5, Employee further
agrees that the Non-Solicitation Period shall be tolled, and shall not run, during the period of any breach by Employee of such covenants. 

 

	6.	 Third Parties; Other Agreements. Employee represents that, except as Employee has
disclosed in writing to the Company, Employee is not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of
his/her employment with the Company, to refrain from competing, directly or indirectly, with the business of such previous employer or any other party or to refrain from soliciting employees, customers or suppliers of such previous employer or other
party. Employee further represents that his/her performance of all the terms of this Agreement and the performance of his/her duties as an employee of the Company do not and will not conflict with or breach any agreement with any prior employer or
other party to which Employee is a party (including without limitation any nondisclosure or non-competition agreement), and that Employee has not and will not disclose to the Company, bring onto the
Company’s premises, or use or induce the Company to use, any confidential or proprietary information or material belonging to any previous employer or others. 

 

	7.	 United States Government Obligations. Employee acknowledges that the Company from
time to time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or
regarding the confidential nature of such work. Employee agrees to be bound by all such obligations and restrictions that are made known to Employee and to take all action necessary to discharge the obligations binding the Company under such
agreements. 

  

	8.	 Miscellaneous. 

 

	 	8.1	 Equitable Remedies. The restrictions contained in this Agreement are necessary for the protection of the
business and goodwill of the Company and are considered by Employee to be reasonable for such purpose. Employee agrees that any breach of this Agreement is likely to cause the Company substantial and irrevocable damage that is difficult to measure.
Therefore, in the event of any such breach or threatened breach, Employee agrees that the Company, in addition to such other remedies which may be available, shall have the right to obtain an injunction from a court restraining such a breach or
threatened breach and the right to specific performance of the provisions of this Agreement, without having to post bond, and Employee hereby waives the adequacy of monetary damages or other remedy at law as a defense to such relief.

  

	 	8.2	 Disclosure of this Agreement. Employee hereby authorizes the Company to notify others, including but not
limited to customers of the Company and any of Employee’s future employers or prospective business associates, of the terms and existence of this Agreement and Employee’s continuing obligations to the Company pursuant to this Agreement.

  

	 	8.3	 No Employment Contract and No License. Employee acknowledges that this Agreement does not constitute a
contract of employment, does not imply that the Company will continue his/her employment for any period of time and does not change the at-will nature of his/her employment. Employee further acknowledges that
no license to any of the Company’s trademarks, patents, copyrights or other proprietary rights is either granted or implied by Employee’s access to and utilization of the Proprietary Information or Developments. 

  
 Page 15 of 18 

 C. Albright 

December 4, 2020 
  Page
 16
 
  

	 	8.4	 Successors and Assigns. This Agreement is binding on Employee and his/her heirs, executors and
administrators, and is for the benefit of the Company and its successors and assigns. The Company may designate affiliates and/or subsidiaries of the Company to have the same rights as the Company under this Agreement, and any obligation owed to the
Company under this Agreement shall be owed to such an affiliate or subsidiary in the same manner as they are owed to the Company. 

  

	 	8.5	 Interpretation. If any restriction set forth in paragraphs 3, 4 or 5 is found by any court of competent
jurisdiction to be unenforceable because it extends for too long a period of time or over too great a scope of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, scope of activities
or geographic area as to which it may be enforceable. 

  

	 	8.6	 Severability. In case any provision of this Agreement shall be invalid, illegal or otherwise
unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

  

	 	8.7	 Waivers. No delay or omission by the Company in exercising any right under this Agreement will operate
as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on any other occasion. 

 

	 	8.8	 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts (but without reference to provisions concerning the conflicts of laws). Any action, suit, or other legal proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement
shall be commenced in Suffolk Superior Court of the Commonwealth of Massachusetts (or, if appropriate, a federal court located within the Commonwealth of Massachusetts), and the Company and Employee each consents to the jurisdiction of such a court.
The Company and Employee each hereby irrevocably waive any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this Agreement. 

 

	 	8.9	 Entire Agreement; Amendment. This Agreement supersedes all prior agreements, written or oral, between
Employee and the Company relating to the subject matter of this Agreement. This Agreement may not be modified, changed or discharged in whole or in part, except by an agreement in writing signed by Employee and the Company. Employee agrees that any
change or changes in his/her duties, salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement. 

  

	 	8.10	 Captions. The captions of the sections and paragraphs of this Agreement are for convenience of reference
only and in no way define, limit or affect the scope or substance of any section or paragraph of this Agreement. 

  

	 	8.11	 Review by Counsel. Employee acknowledges that he/she had the right to consult with legal counsel before
signing this Agreement. 

  
 Page 16 of 18 

 C. Albright 

December 4, 2020 
  Page
 17
 
  

 EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY READ THIS AGREEMENT, THAT EMPLOYEE HAD THE RIGHT TO
CONSULT WITH COUNSEL BEFORE SIGNING BELOW, AND THAT EMPLOYEE WAS PROVIDED WITH THIS AGREEMENT ON THE EARLIER OF THE SUBMISSION OF A FORMAL OFFER OF EMPLOYMENT OR TEN BUSINESS DAYS BEFORE COMMENCEMENT OF EMPLOYMENT. EMPLOYEE UNDERSTANDS AND AGREES TO
ALL OF THE PROVISIONS IN THIS AGREEMENT. 
  

							
	AFFFINIA THERAPEUTICS INC.	 	                            	  	CHARLES ALBRIGHT, Ph.D.
				
	By:	 	 /s/ Rick Modi
	 		  	 /s/ Charles Albright

	Name:	 	Rick Modi	 		  	Date: 12/20/2020
	Title:	 	Chief Executive Officer	 	
				
	Date:	 	12/20/2020	 		  	

 EXHIBIT B 

USCIS FORM I-9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]